Literature DB >> 219319

Progressive systemic sclerosis (PSS) and malignancy, pulmonary and non-pulmonary.

J H Talbott, M Barrocas.   

Abstract

In contrast to the 15-20% incidence of the coexistence of acute dermatomyositis-polymyositis and malignancy, it has been accepted traditionally that the association of progressive systemic sclerosis, a disease with several features that may overlap the former condition, and malignancy is purely fortuitous. This experience has not been altered by the material presented in this review. However, the factual coexistence has been illuminated by a review of the pertinent literature and presentation of 12 previously unpublished case reports. Four cases concern pulmonary malignancies in PSS; eight are of an associated non-pulmonary malignancy. In the first group, the development of a malignancy superimposed on the chronic fibrosing changes in the lungs of PSS does not seem so strange, particularly in view of a possible immunologic reaction by collagen in considering pathogenesis. This immunologic process might be similar to a related immunologic process responsible for the development of malignant cells in pulmonary and other tissue, where normal cells usually are found. The high incidence of males is related to the high incidence of males in Veterans Administration Hospitals, the principal population source of these cases.

Entities:  

Mesh:

Year:  1979        PMID: 219319     DOI: 10.1097/00005792-197903000-00006

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  10 in total

1.  Systemic sclerosis following anti-androgenic treatment for prostatic adenocarcinoma.

Authors:  N Giordano; L Magaro; L Fattorini; P Marcucci; E Battisti; A Fioravanti; R Marcolongo
Journal:  Clin Rheumatol       Date:  1993-03       Impact factor: 2.980

2.  Chromosome abnormalities in peripheral lymphocytes from patients with progressive systemic sclerosis.

Authors:  F Takeuchi; K Nakano; H Yamada; E Kosuge; M Hirai; H Maeda; Y Moroi
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

3.  Scleroderma and malignancy: an epidemiological study.

Authors:  A K Rosenthal; J K McLaughlin; M S Linet; I Persson
Journal:  Ann Rheum Dis       Date:  1993-07       Impact factor: 19.103

Review 4.  Association between systemic sclerosis and breast cancer: eight new cases and review of the literature.

Authors:  David Launay; Rozenn Le Berre; Pierre-Yves Hatron; Jean-Philippe Peyrat; Eric Hachulla; Bernard Devulder; Mohamed Hebbar
Journal:  Clin Rheumatol       Date:  2004-12       Impact factor: 2.980

5.  Intestinal perforation. A common complication of scleroderma.

Authors:  E C Ebert; F M Ruggiero; J R Seibold
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

6.  Systemic sclerosis in association with multiple primary pulmonary malignancy--a marker of internal malignancy?

Authors:  M J Goodfield; L G Millard
Journal:  Postgrad Med J       Date:  1988-11       Impact factor: 2.401

Review 7.  Paraneoplastic rheumatic disorders: a review.

Authors:  R C Butler; J M Thompson; A C Keat
Journal:  J R Soc Med       Date:  1987-03       Impact factor: 18.000

8.  Haematological Malignancies in Systemic Sclerosis Patients: Case Reports and Review of the World Literature.

Authors:  M Colaci; D Giuggioli; C Vacchi; C Ferri
Journal:  Case Rep Rheumatol       Date:  2017-05-04

9.  Squamous Cell Lung Cancer Associated With Systemic Sclerosis.

Authors:  Nobuhiro Kanaji; Masaya Okuda; Hiroaki Dobashi; Tomohiro Kameda; Akira Tadokoro; Risa Wakiya; Norimitsu Kadowaki; Shuji Bandoh
Journal:  J Clin Med Res       Date:  2015-09-25

10.  Anti scl-70 antibody positive systemic sclerosis in a patient with lung cancer: a paraneoplastic or a purely coincidental phenomenon?

Authors:  Anusree Gangopadhyay; Sumit Sen; Biswanath Naskar; Gobinda Chatterjee
Journal:  Indian J Dermatol       Date:  2013-09       Impact factor: 1.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.